Boston Scientific Acquires SoniVie for USD 360M
Categories: Capital Markets
Boston Scientific, a leading U.S.-based medical technology company, has acquired SoniVie Ltd., an Israeli firm specializing in intravascular ultrasound treatment, for USD 360 million.
The deal includes an additional USD 180 million contingent on achieving a regulatory milestone. SoniVie’s TIVUS™ Intravascular Ultrasound System is designed for pulmonary hypertension and other cardiovascular conditions, strengthening Boston Scientific’s interventional cardiology portfolio.
Gornitzky represented Boston Scientific, with legal counsel from partners Daniel Marcus, Shimrit Roznek, and Yoni Raff, supported by associates Shachar Aharoni and Shira Brami. The firm collaborated closely with Latham & Watkins, as U.S. counsel.
SoniVie Ltd was represented by K&L Gates.